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An approximate 140-fold purification of the A, adenosine receptor of bovine cerebral cortex has been obtained via affinity chromatography. The 
affinity column consists of Affi-Gel 10 coupled through an amide linkage to XAC, a high-affinity A, adenosine receptor antagonist. As assessed 
by PH]XAC binding, bovine brain membranes solubilized with the detergent CHAPS had a specific binding activity of 1 .I pmol/mg protein. Interac- 
tion of solubilized A, adenosine receptors with the XAC-Affi-Gel was biospecific and 30% of the receptor activity was bound by the gel. Demonstra- 
tion of PH]XAC binding in the material eluted from the column with R-PIA required insertlon of receptor into phospholipid vesicles. The specific 
activity of the affinity column purified receptor was 146 + 22 pmol/mg protein with typically 5-15s of the bound receptor recovered. The purified 
receptor displayed high-affinity antagonist binding and bound agonists with the potency order expected of the bovine brain A, adenosine receptor: 
R-PIA > SPIA > NECA. In purified preparations, the photoaffinity probe rZ51]PAPAXAC-SANPAH specifically labelled a protein of molecular 
mass 38000 which has previously been shown to be the A, adenosine receptor binding subunit. 
Adenosine receptor; Affinity chromatography 
1. INTRODUCTION 
Adenosine produces a variety of effects in the cardio- 
vascular, central nervous, pulmonary and immunologic 
systems [1,2]. Many of the effects of adenosine occur as 
the result of its interaction with a specific cell surface 
receptor termed the A1 adenosine receptor (AIAR). The 
AlAR binding subunit in bovine brain and rat brain and 
fat is a glycoprotein of M, 38 000 [3,4]. Molecular prop- 
erties of the AIAR, including its ligand binding activity 
and interaction with the associated G protein, have 
begun to be studied in solubilized preparations [5-81. 
Complete determination of the receptor’s structure as 
well as a more complete characterization of its function 
at a molecular level requires its purification. This report 
describes the synthesis and use of a biospecific affinity 
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column to obtain substantial purification of the AlAR 
from solubilized bovine cerebral cortex membranes. 
The affinity column consists of Affi-Gel 10 coupled 
through an amide linkage to XAC, a selective and high- 
affinity A1 adenosine receptor antagonist [9]. 
2. MATERIALS AND METHODS 
2.1. Synthesis of XAC-Affi-Gel 
Affi-Gel 10 (10 ml) was washed with 250 ml of DMSO over 15 min. 
The slurry was added to 20 ml of a 75% DMSO/25% ethanol solution 
containing 5 mg of XAC and incubated at 22’C for 15 h. The gel was 
washed extensively with DMSO to remove uncoupled XAC and the 
wash solution was gradually increased to 100% HzO. Finally, the gel 
was washed with 200 mM Tris-acetate, pH 8.0, for 24 h at 5°C to 
block any remaining free ester groups. 
2.2. Membrane solubilization 
Bovine cerebral cortex membranes prepared as previously described 
[7] were washed with 50 mM Tris, 5 mM EDTA, pH 8.26, at 5°C and 
then treated with adenosine deaminase (10 U/ml) for 30 min at 37°C. 
Membranes were pelleted by centrifugation and resuspended at a 
detergent/protein ratio of -2.5/l in 1% CHAPS, 20 mM Tris, 
5 mM EDTA, and 100 mM NaCI, pH 7.4, at 5°C. The mixture was 
dounce homogenized with 10 strokes and stirred on ice for 30 min 
followed by centrifugation at 105 000 x g for 40 min. The superna- 
tant was taken as the soluble fraction and diluted with an equal 
volume of 50 mM Tris, 1 mM EDTA, and 125 mM NaCI, pH 7.4, at 
5°C containing 20 pM Gpp(NH)p. 
2.3. Affinity chromatography 
Prior to a chromatography cycle, the XAC-Affi-Gel was equi- 
librated with 0.330/o CHAPS, 50 mM Tris, 1 mM EDTA, and 
292 
Published by Elsevier Science Publishers B. V. (Biomedical Division) 
00145793/89/$3.50 0 1989 Federation of European Biochemical Societies 
Volume 257, number 2 FEBS LETTERS November 1989 
125 mM NaCl, pH 7.4, at 5°C (Buffer A}. Typically, lOO-200 ml of 
solubilized membranes (100-200 pmol of receptor) were incubated 
with approximately 4 ml of XAC-Affi-Gel either batchwise with slow 
rotation or by recycling at a flow rate of 30 ml/h. For either method, 
incubation was conducted at 5°C for 10 h. The soluble preparation 
was then removed and the gel washed batchwise with 15 ml of Buffer 
A for 5 min. This wash buffer was removed and the gel then washed 
with Buffer A at a flow rate of 30 ml/h for 45 min. All washing was 
performed at YC. The get was then brought to room temperature for 
elution. The elution buffer consisted of 0.05% L-a-phosphatidyl- 
choline suspended via sonication in 30 mM Hepes, 5 mM MgCl2, and 
100 mM NaCl diluted with an equal volume of 0.66% CHAPS, 
50 mM Tris, 10 mM MgClz, and 250 mM NaCl. R-PIA was added to 
give a final concentration of 2 FM and the buffer was made pH 6.8 
at 22°C. The elution buffer was applied to the gel at IO ml/h and the 
eluate collected over the first 10 min was discarded. Eluted material 
was collected on ice over the next 65 min and immediately desalted at 
5°C on Sephadex G50 columns preequilibrated with 30 mM Hepes, 
5 mM MgC12, and 100 mM NaCl, pH 7.4. 
2.4. Radioligand binding assays 
Binding assays in soluble preparations were performed as previous- 
ly described [7]. Saturation assays of affinity chromatography- 
purified receptor consisted of 150 pl of phospholipid reconstituted 
material, 50 pl of [‘HIXAC (0.2-2.0 nM) and 50 pl of Hz0 or 10 FM 
R-PIA to define non-specific binding. Gpp(NH)p was present in all 
assay tubes at a concentration of 10 FM. In competition binding ex- 
periments, the assay consisted of 150 pl of receptor preparation, 50 pl 
of 0.5 nM i3HJXAC and 50 ~1 of competitor. All incubations were for 
2 h at 22°C and terminated by washing with three 3 ml aliquots of 
0.01% CHAPS in 50 mM Tris, 10 mM MgC12, and 1 mM EDTA with 
rapid vacuum filtration over polyethylenimine-treated glass fiber 
filters. Saturation and competition curves were analyzed using a non- 
linear least-squares curve fitting technique with statistical analysis as 
previously described [lo]. 
2.5. P~atoaf~nity iabeiling 
[‘*‘I]PAPAXAC-SANPAH was synthesized as described [1 l]. 
Labelling was performed by incubating 1 ml of reconstituted affinity 
column eluate with 0.8 nM [‘251]PAPAXAC-SANPAH for 45 min at 
25°C. The mixture was diluted to 3 ml with 30 mM Hepes, 5 mM 
MgC12, and 100 mM NaCl, pH 7.4, and exposed to UV light for 3 min 
from a model UVCG-25 mineral lamp. The mixture was then cen- 
trifuged at 105 000 x g for 1 h. The pellet was solubilized in SDS buf- 
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fer and subjected to polyacrylamide gel 
radiography as previously described [I 11. 
2.6. Protein assays 
electrophoresis and auto- 
All protein concentrations were determined by the method of Brad- 
ford 1121 with the exception of the affinity column-purified material 
which was analyzed by either the aminoschwarz method of Schaffner 
and Weismann 1131 or the Bradford assay. 
3. RESULTS 
Solubilization conditions were optimized to ensure 
the maximal efficiency of solubilization and stability of 
the AIAR. We tested a variety of conditions to enhance 
[3H]XAC binding and found that eIimination of MgCl2 
and the addition of NaCl and Gpp(NH)p enhanced 
solubilization and stabilization of the receptor. As 
determined with [‘H]XAC binding, maximum binding 
capacity of the solubilized membranes (without 
Gpp(NH)p and with MgClt) was - 1 pmol/mg protein, 
however, this value declined by approximately 50% 
after 16 h storage at 5°C. It was then determined that 
the exclusion of MgC12 and the addition of Gpp(NH)p 
to the postsolubilization diluting buffer, not only in- 
creases 13H]XAC binding, but stabilizes the solubilized 
receptor so that the B,, value declines by less than 10% 
after storage at 5°C for 16 h. Using these conditions, 
approximately 50-60% of the membrane receptor is 
solubilized. 
Maximum binding of the AlAR to the XAC-Affi-Gel 
occurs after approximately 10 h of incubation at 5°C. 
At this time, approximately 30% of the applied AlARs 
adsorb to the XAC-Affi-Gel while less than 5% of the 
total protein is retained on the column. Both the length 
of time and the volume of the wash buffer were found 
to be important. Less washing decreased fold purifica- 
tion, while more prolonged washing resulted in decreas- 
ed yield. 
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Fig. 1. [3H]XAC saturation curves in (A) solubilized bovine brain membranes and (B) XAC-Affi-Gel-purified preparation. Membrane solubiliza- 
tion, affinity chromatography and binding assays were performed as described in section 2. Non-specific binding was defined with 10 /tM R-PIA 
or 5 mM theophylline. Gpp(NH)p (10 FM) was present in all assay tubes. These plots are representative of 5 similar experiments. 
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Fig.2. Agonist competition for [3H]XAC binding in (A) solubilized bovine brain membranes and (B) XAC-Affi-Gel-purified preparation. Mem- 
brane solubilization, affinity chromatography and binding assays were performed as described in section 2. The final concentration of [‘H]XAC 
was -0.5 nM in both assays. These plots are representative of 3 similar experiments. 
The results of a typical purification procedure with 
XAC-Affi-Gel are presented in fig. 1. In 5 experiments, 
an average specific activity of 146 + 22 pmol/mg pro- 
tein was obtained for XAC-Affi-Gel-purified receptor. 
This represents an approximate 140-fold purification of 
the AiAR from the starting solubilized material (Bmax 
= 1 .lO f 0.09 pmol/mg). For both the purified and 
solubilized receptor, [‘H]XAC binding is saturable and 
of high affinity. KD values are 0.31 f 0.02 nM and 
0.53 + 0.05 nM for solubilized membranes and purified 
receptor, respectively. In solubilized membranes, at 
[3H]XAC concentrations slightly above the KD, non- 
specific binding represents approximately 10% of total 
binding. This value is 25-30% in the reconstituted 
material with the increase most likely attributable to the 
presence of phospholipids. The B,,, value calculated 
for the purified product is likely an underestimation 
since the efficiency of insertion of proteins into phos- 
pholipid vesicles is likely less than 100%. Inclusion of 
phospholipids in the elution buffer and subsequent in- 
sertion of receptors into vesicles is required for AiAR 
activity as assessed by [3H]XAC binding. Most of the 
AiAR activity was eluted between 10 and 65 min and 
hence these aliquots were pooled for all subsequent 
assays. The interaction of the receptor with XAC-Affi- 
Gel is biospecific as no [3H]XAC binding activity can be 
recovered if R-PIA is omitted from the phospholipid 
elution buffer or if the solubilized preparation is ap- 
plied to Affigel 10 or Sepharose 6B without XAC coup- 
led to it. AlAR activity comparable to that presented in 
fig.1 can be obtained if theophylline (5 mM), an 
adenosine receptor antagonist, is used as a counter- 
ligand during elution (data not shown). Typically, 
5- 15 % of the receptor activity bound to the affinity col- 
umn is recovered in the eluate. The yield of affinity- 
purified receptor as calculated from starting solubilized 
membranes is therefore approximately 3 %. 
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To demonstrate that the purified receptor possesses 
all the characteristics expected of the AiAR, we fully 
characterized the affinity-purified preparation. First, 
antagonist saturation curves demonstrate high affinity, 
saturable binding with no change in KD compared to 
solubilized AiAR. Second, in purified preparations, 
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Fig.3. Photoaffinity labelling of XAC-Affi-Gel-purified AI 
adenosine receptor with [r*‘I]PAPAXAC-SANPAH. Chromatog- 
raphy and photoaffinity labelling were performed as described in sec- 
tion 2. Labelling was performed in the absence (control) or presence 
of 5 mM theophylline. Following labelling, the sample was solubiliz- 
ed in SDS and electrophoresed on a 12% acrylamide gel. The posi- 
tions of iodinated molecular mass standards are shown to the left. 
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agonists compete for [3H]XAC binding in the order of 
R-PIA> S-PIA> NECA which is as expected for the 
bovine cerebral cortex AiAR [4]. The results of a 
representative competition binding experiment in 
solubilized membranes and purified preparation are 
shown in fig.2. For the experiment shown, the ZCSO 
values of R-PIA, S-PIA and NECA are increased by 
52-, 90- and 124-fold, respectively, in purified as com- 
pared to starting material. This decrease in affinity is 
agonist specific and has been observed in other receptor 
systems following purification [14]. The AiAR an- 
tagonist, XCC, displayed a similar affinity in solubiliz- 
ed and partially purified material (data not shown). 
Finally, to ensure that we had purified the same 
AiAR binding subunit as that present in membranes, 
we photoaffinity-labelled the purified AlAR with [lz51]- 
PAPAXAC-SANPAH (an AiAR selective photoaffini- 
ty probe) [4, Ill. As shown in fig.3, the same 38 000 Da 
protein is specifically labelled in the affinity-purified 
preparation as that previously demonstrated [4,11]. 
4. DISCUSSION 
In this report we describe the synthesis and use of 
XAC-Affi-Gel to obtain an approximate 140-fold 
purification of the AiAR of bovine cerebral cortex. 
Through the exclusion of MgClz during the solubiliza- 
tion and subsequent treatment of the preparation with 
Gpp(NH)p, we have solubilized the AiAR in a state 
which binds antagonists with high affinity and is stable 
over the time required for completion of the affinity 
chromatography procedure. This procedure was re- 
quired in that, in the presence of MgCl2 and the absence 
of guanine nucleotides, the solubilized receptor was 
rather labile as assessed by radioligand binding. A 
similar finding has been reported by others [ 151. 
The interaction of the AlAR with the XAC-Affi-Gel 
is biospecific as the receptor does not bind to the sup- 
port matrix itself and the presence of R-PIA as a coun- 
terligand is required to obtain receptor activity in the gel 
eluate. AiAR binding activity is evident in the XAC- 
Affi-Gel product only under the elution conditions 
described. Phospholipids must be present in the elution 
buffer and the eluate must be desalted to permit the 
removal of CHAPS and insertion of the receptor into 
phospholipid vesicles. A similar requirement for phos- 
pholipid reconstitution procedure was reported for the 
purification of the Dz-dopamine receptor via affinity 
chromatography [16]. It is not known if the phospho- 
lipids are necessary for the removal of the receptor from 
the gel, the stabilization of the receptor once it is 
dissociated from the gel, or if they act to allow the 
receptor to assume the conformation necessary to 
demonstrate [3H]XAC binding. 
The affinity-purified receptor possesses the charac- 
teristics expected of the AiAR. The binding of an- 
tagonists displays similar properties in both solubilized 
membranes and the affinity column eluate. Further- 
more, adenosine analogs bind to the partially purified 
preparation in the order expected for bovine brain 
AiAR [4]. Finally, as it does in membranes, the photo- 
affinity probe [1251]PAPAXAC-SANPAH specifically 
labels a protein of A4, 38000 in the affinity column 
eluate. This protein is the AiAR binding subunit [4,1 I]. 
The fold purification of the AlAR we report is ap- 
preciable, however, the yield remains less than 10%. A 
loss in the yield may in part be attributable to the de- 
salting procedure which follows elution as well as the 
less than 100% efficiency of insertion of receptors into 
phospholipid vesicles. It is possible that a population of 
receptors are eluted from the gel but are in a conforma- 
tion which is no longer recognized by [3H]XAC. Recep- 
tor degradation during the procedure could also dimin- 
ish the recovery of receptors. However, the use of 
several protease inhibitors or the stabilizing agent, 
glycerol, during the solubilization and chromatography 
steps provided no improvements in the yield of recep- 
tors. 
The theoretical specific activity of the AiAR, based 
on a molecular mass of 38000 Da for the binding sub- 
unit [3,4] is 26 nmol/mg. Therefore, a further 
150-200-fold purification of the affinity column- 
purified receptor we have obtained is required for a 
homogeneous preparation. Techniques such as wheat 
germ agglutinin chromatography and high- 
performance steric exclusion liquid chromatography 
may permit for the complete purification of the AiAR 
thus permitting the determination of its structure and 
further study of the molecular mechanisms involved in 
its signal transduction activity. 
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